Naslov
Ziprasidone in treatement of patients with schizophrenia
(Ziprasidone in treatment of patients with schizophrenia)

Autori
Folnegović-Šmalc, Vera ; Uzun, Suzana ; Mimica, Ninoslav ; Ljubin, Tajana ; Markan-Šošić, Vera

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Periodicum biologorum 103 (Suppl. 1) / Vitale, Branko - Zagreb : Periodicum biologorum, Hrvatsko prirodoslovno društvo, 2001, 107-107

Skup
Third Croatian Congress of Pharmacology With International Participation

Mjesto i datum
Zagreb, Hrvatska, 18.09.2001. - 21.09.2001

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
ziprasidone; treatment; schizophrenia

Sažetak
Phenothiazine and butyrophenone derivates remain the best known and most frequently used agents for treating schizophrenia, and are also useful in the treatment of bipolar disorder, especially mania. Use of traditional antipsychotic drugs has three principal limitations. First, approximately 20-40% of treated patients develop extrapyramidal symptoms, side effects that appear to be linked to the blockage of dopamine receptors in the striatal regions of the brain. Second, a debilitating chronic motor syndrome, tardive dyskinesia, arises after long-term antipsychotic therapy in 15 to 30% of patinets. Third, antipsychotic drugs are ineffective in roughly one third of schizophrenic patients, and appear particularly ineffective against the negative symptoms of schizophrenia. Although typical phenothiazine and butyrophenone derivates continue to be widely prescribed, much attention has been focused on newer agents such as ziprasidone. Ziprasidone was developed with the intent of findineg the compound that potentialy blokcs D2 receptors, but that binds with even greater affinity to cerebral 5-HT2A receptors. In receptor affinity studies, ziprasidone weekly desplaces mepyramine from H1 receptors and inhibits histamine-stimulated contractions. Data from clinical studies indicate that ziprasidone is an effective agent in the short-term and long-term menagement of psychosis. One 52-week study has shown that ziprasidone can significantly reduce the risk of relapse in hospitalised individuals with chronic schizophrenia. Ziprasidone effectively ameliorates positive, negative, and depressive symptoms associated with psychosis. Concideration of all relevant data suggests the optimal dose for the tretment of psychosis is 40 to 80 mg BID. Ziprasidone was well tolerated by adult subjects. The most frequently reported treatment- emergent adverse events reported in ziprasidone-treated subjects were insomnia, headache and somnolence. However, weight-gain - a typical side-effect of antipsychotics- was not observed with this novel drug. Conclusion: In this presentation overview of novel antipsychotic ziprasidone has been given and the design of all three studies in wich Croatian investigators took part was fully described. Although final analysis is not yet done, we can conclude that our experience with ziprasidone through 12 week doble-blind (ziprasidone versus risperidone in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder) study ; a one year doble-blind study (ziprasidone versus olanzapine in the tretment of chronic schizophrenia and schizoaffective disorder) and one year open- label extension confirms the above mentioned data.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA